NewLimit CEO Says AI Matches Recombinant DNA Scale in Biotech

A tweet from @technooptimist1 quoted Jacob Kimmel, CEO of NewLimit, stating that artificial intelligence in biopharma is the first revolution of the same scale as recombinant DNA and the first technology disruption on the same order of magnitude. The post presented the remarks as part of daily clips featuring leading techno-optimists and ended mid-sentence on expected future developments. No additional confirmation or context appears in the packet.